Signaling to p53: breaking the MDM2-p53 circuit
Article Quality & Performance Metrics
Readership in this journal
PopularRanked #36 of 72 articles by views in Cell
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
| Reference Key |
c1998cellsignaling
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Prives C;; |
| Journal | Cell |
| Year | 1998 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
animals
humans
pubmed abstract
nih
national institutes of health
national library of medicine
signal transduction*
cyclin-dependent kinase inhibitor p16 / genetics
nuclear proteins*
pmid:9778240
doi:10.1016/s0092-8674(00)81774-2
c prives
proto-oncogene proteins / metabolism*
proto-oncogene proteins c-mdm2
tumor suppressor protein p53 / metabolism*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
ZincirX productsfrom the team behind Journament
-
PatentYazar
Patent drafts for the EPO, USPTO and TürkPatent
From inventor notes to a DOCX draft: description, claims, abstract. The machine drafts, the attorney signs.
See how it works (opens in a new tab) -
Projenator
Have a project idea? Score and plan it with AI
AI scores your idea in five dimensions and builds a phased plan. Your first project is free, no card needed.
Start your first project (opens in a new tab)
Cookies
We use strictly necessary cookies to run the site and keep you signed in. With your permission we would also use Google Analytics to see how the site is used, and Google AdSense to show ads on journal and article pages. Both stay off unless you accept, and you can change your mind at any time. How we use cookies · KVKK notice (Türkiye)
Cookie settings
Comments
No comments yet. Be the first to comment on this article.